Eyegate Pharmaceuticals (NASDAQ:EYEG) received a $3.00 target price from equities research analysts at HC Wainwright in a research note issued on Monday, August 6th. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 435.71% from the stock’s previous close.
The analysts wrote, “Our price target is derived from a discounted cash flow-based asset value of $230M for EGP-437 and OBG, using a 15% discount rate and 1% terminal growth rate. We ascribe 80% and 25% probabilities of success to EGP-437 and OBG, respectively. Investment risks include: (1) failure of EGP-437 or OBG in clinical trials; (2) failure of EGP-437 or OBG to secure regulatory approval; (3) failure of EGP-437 or OBG to achieve commercial success due to reimbursement, penetration rate, and/or competition; and (4) dilution risk.””
Separately, ValuEngine upgraded Eyegate Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last posted its quarterly earnings data on Friday, August 3rd. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.81 million. analysts forecast that Eyegate Pharmaceuticals will post -0.34 earnings per share for the current fiscal year.
Eyegate Pharmaceuticals Company Profile
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Recommended Story: Market Capitalization
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.